PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study

Donald M. Lyall*, Joey Ward*, Maciej Banach, George Davey Smith, Jason M. R. Gill, Jill P Pell, Michael V Holmes, Naveed Sattar*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

2 Citations (Scopus)
7 Downloads (Pure)

Abstract

Background: PCSK9 inhibitors lower low-density lipoprotein (LDL) cholesterol and are efficacious at reducing vascular disease, however questions remain about potential effects on cognitive function.

Method: We examined the association of genetic variants in PCSK9 with continuous measures of cognitive ability in UK Biobank. Six independent polymorphisms in PCSK9 were used in up to 337,348 individuals.

Results: The PCSK9 allele score was associated with a lower risk of CHD, and worse log reaction time.

Conclusion: We are unable to rule out meaningful associations of PCSK9 genetic variants with cognition, emphasising continued pharmacovigilance for patients currently treated with PCSK9 inhibitors.
Original languageEnglish
Pages (from-to)241–244
Number of pages4
JournalArchives of Medical Science
Volume17
Issue number1
DOIs
Publication statusPublished - 5 Jan 2021

Bibliographical note

Publisher Copyright:
© 2020 Termedia & Banach.

Fingerprint

Dive into the research topics of 'PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study'. Together they form a unique fingerprint.

Cite this